Tracey Wiley
Nurse Practitioner · Chambersburg, PANPI 1194785162
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $79,861 of the $101,385 with a category attached, or 78.8%. 18 manufacturers reported payments, led by Novo Nordisk at 55.7% of the total. Among nurse practitioner clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 409 payments — averaging $247.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$56K
- Abbott$37K
- Mannkind Corporation$3K
- Sanofi-aventis U.S. LLC$2K
- Lilly USA, LLC$1K
- Dexcom, Inc.$450
- plus $2K from 12 others
What the payments were for
- Consulting fees$1,4401%
- Speaking & faculty fees$79,86179%
- Travel & lodging$11,17111%
- Food & beverage$8,8039%
- Education$1090%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 97 | $56,432 |
| Abbott | 108 | $37,366 |
| Mannkind Corporation | 9 | $2,631 |
| Sanofi-aventis U.S. LLC | 30 | $1,675 |
| Lilly USA, LLC | 64 | $1,047 |
| Dexcom, Inc. | 20 | $450 |
| Insulet Corporation | 19 | $402 |
| Tandem Diabetes Care, Inc. | 16 | $352 |
| Corcept Therapeutics | 11 | $278 |
| Boehringer Ingelheim | 12 | $224 |
| Bayer | 6 | $144 |
| Xeris Pharmaceuticals, Inc. | 6 | $117 |
| Cequr Corporation | 2 | $74 |
| Medtronic | 3 | $67 |
| Zealand Pharma US, Inc. | 2 | $43 |
| Ascensia Diabetes Care US Inc. | 2 | $40 |
| Sequel Med Tech, LLC | 1 | $24 |
| Novartis | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FREESTYLE LIBRE 3$34,671
- RYBELSUS$25,915
- Ozempic$20,287
- V-GO$2,350
- FreeStyle Libre 2$963
How this compares
$101,385 in reported general payments places this provider in the 95th percentile of 4,059 nurse practitioner providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 697 | $1,226,774 |
| JardianceEmpagliflozin | 755 | $853,388 |
| TrulicityDulaglutide | 227 | $406,278 |
| Tresiba Flextouch U-200Insulin Degludec | 230 | $329,104 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 98 | $205,645 |
| Tresiba Flextouch U-100Insulin Degludec | 314 | $197,124 |
| MounjaroTirzepatide | 89 | $161,258 |
| Humulin R U-500Insulin Regular, Human | 43 | $131,522 |
| JanuviaSitagliptin Phosphate | 142 | $123,007 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 29 | $114,800 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 95 | $107,408 |
| FiaspInsulin Aspart (Niacinamide) | 76 | $100,850 |
| Novolog FlexpenInsulin Aspart | 308 | $100,764 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 92 | $87,091 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 49 | $60,682 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Fiasp, Novolog, Tresiba | $56,432 | $1,388,057918 claims |
| Boehringer IngelheimJardiance, Synjardy, Synjardy Xr, Tradjenta | $224 | $953,169833 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $1,047 | $585,412383 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $1,675 | $60,68249 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,059 nurse practitioner providers in Pennsylvania.
Other nurse practitioner in Chambersburg
- Patricia ManganPhiladelphia$360K
- Lisa CocoPhiladelphia$230K
- Elisabeth BaidalPhiladelphia$151K
- Suzanne McGettiganPhiladelphia$108K
- Pamela LorditchJohnstown$81K
- Nana BernaskoHershey$81K
- Dawn JeanneratClarion$78K
- Carolyn GrandePhiladelphia$71K
- Nicole WaetzmanStrafford$66K
- Faith MutalePhiladelphia$62K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.